Corcept Therapeutics Incorporated (FRA:HTD)

Market Cap	7.79B
Revenue (ttm)	631.70M
Net Income (ttm)	89.20M
Shares Out	n/a
EPS (ttm)	0.74
PE Ratio	87.28
Forward PE	73.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400
Average Volume	20
Open	71.12
Previous Close	71.86
Day's Range	71.12 - 71.12
52-Week Range	48.28 - 105.30
Beta	n/a
RSI	61.43
Earnings Date	Feb 18, 2026

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HTD

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD